Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD

Neural Plasticity

Volumn 11, Issue 1-2, 2004, Pages 77-95

  Carboni, Ezio ^a   Silvagni, Alessandra ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Dopamine; Noradrenaline; Nucleus accumbens; Prefrontal cortex; SHR; VMAT2

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; ATOMOXETINE; BENZATROPINE; CALMODULIN BINDING PROTEIN; CANNABINOID RECEPTOR; CATECHOLAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; METHYLPHENIDATE; NEUROMODULIN; NIFEDIPINE; NOMIFENSINE; NORADRENALIN TRANSPORTER; POTASSIUM ION; PROTEIN KINASE C; SEROTONIN TRANSPORTER; SYNAPSIN I; TRICYCLIC ANTIDEPRESSANT AGENT; VERATRIDINE;

ANIMAL MODEL; ATTENTION DEFICIT DISORDER; BRAIN SLICE; CATECHOLAMINE RELEASE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG CHOICE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME ACTIVATION; EXPERIMENTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL CULTURE; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE STEADY POTENTIAL; NONHUMAN; NUCLEUS ACCUMBENS; POTASSIUM TRANSPORT; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; RETROSPECTIVE STUDY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; SYNAPSE VESICLE; SYNAPTOSOME;

EID: 4143105995     PISSN: 20905904     EISSN: None     Source Type: Journal    
DOI: 10.1155/NP.2004.77     Document Type: Review

References (126)

1. Almaric M, Koob GF. 1993. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog Brain Res 99: 209-226.
2. Anderson BB, Chen G, Gutman dopamine, Ewing AG. 1998. Dopamine levels of two classes of vesicles are differentially depleted by amphetamine. Brain Res 788: 294-301
3. Berger DF, Sagvolden T. 1998. Sex differences on operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 94:73-82.
4. Biederman J, Spencer T, Wilens T. 1997 Psychopharmacology. In: Wlener JM, ed, Textbook of Child and Adolescent Psychiatry. Washington DC, USA: American Psychiatric Press; 779-813.
5. Bouyer JJ, Joh TH, Pickel VM. 1984. Ultrastructural localization of tyrosine hydroxylase in rat nucleus accumbens. J Comp Neurol. 227: 92-103.
6. 3H]dopamine from striatal slices and synaptosomes. J Pharmacol Exp Ther 240:177-86
7. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711
8. Cadoni C, Pinna, A, Russi G, Consolo S, Di Chiara G. 1995. Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry. Neuroscience 65: 1027-1039.
9. Carboni E, Imperato A, Perezzani L, Di Chiara G. 1989. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
10. Carboni E, Tanda GL, Frau R, Di Chiara G. 1990. Blockade of the noradrenaline carrier increases extracellular concentration in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
11. Carboni,E, Spielowoy C, Vacca C, Nonsten-Bertrand M, Giros B, Di Chiara G. 2001. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice locking the dopamine transporter. J Neurosci 21: RC141
12. Carboni E. 2003. Microdialysis coupled with electrochemical detection. A way to investigate brain monoamine role in freely moving animals. Methods Mol Med 79: 415-432.
13. Carboni E, Silvagni A, Valentini V, and Di Chiara G. 2003. Effact of amphetimine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats. An in vivo microdialysis study. Neorosci Biobehav Rev 27. 653-659.
14. Cerrito F, Casazza G, Levi G, Raiteri M. 1980. Evidence for a similar compartmentation of recaptured and endogenously synthesized dopamine in striatal synaptosomes. Nourochem Res 5:115-21.
15. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. 2003. Dopamine transporter density in the basal ganglia massed with [(123)I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30:306-311.
16. Chiueh CC, McCarty R., 1991. Sympatho-adrenal hyperreactivity to footshock stress but not to cold exposure in. spontaneously hypertensive rats. Physiol Behav X6: 85-89.
17. Clements JD. 1996. Transmitter timecourse in the synaptic cleft: its role In central synaptic function. Trends Neurosci 19:163-171.
18. + gradient reversal increase striatal synaptosomal dopamine synthesis through carrier-mediated efflux of dopamine. Biochem Pharmacol 35: 3123-3130.
19. Davids E, Zhang K, Tarazi FI, Baldesserini RJ. 2003. Animals models of attention-deficit hyperactivity disorder. Brain Res Rev 42:1-21.
20. Deutch AY, Cameron DS. 1992. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49-56.
21. Di Chiara G. 1990. In vivo train dialysis of neurotransmitters. Trends Pharmacol Sci 11: 116-121.
22. Di Chiara G, Acquas E, Carboni E. 1992. Drug motivation and abuse: a neurobiological perspective. Ann N Y Acad Sci 654: 207-219.
23. Di Chiara G, Tanda G, and Carboni E. 1996. Estimation of in-vivo neurotransmitter release by brain microdialysis: the issue of validity. Behav Pharmacol 7: 640-657.
24. Di Chiara G. 2002. Nucleus accumbens shell and core dopamine: diffirential role in behavior and addiction. Behav Brain Res 137:75-114.
25. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madsras BK, Fishman AJ. 1999. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354: 2132-2133.
26. Dunwiddie T, Mueller A, Basile A. 1983. The use of brain slices in central nervous system pharmacology. Fed Proc 42: 2891-2898.
27. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, et al. 1999. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl). 142: 295-301.
28. Faraone SV, Biederman J. Pathophysiology of attention-deficit/hyperactivity disorder. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds, Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 577-596.
29. Ferguson SA, Gough BJ, Cada AM. 2003. In vivo basal and amphetamine-induced striatal dopamine and metabolite levels are similar in the spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley male rats. Physioi Behav 80: 109-114.
30. Fibiger HC, Phillips AG. 1986. Reward, motivation, cognition: psychobiology of mesentelencephalic dopamine systems. In: Mountcastle VB, Bloom FE, Geiger SR, eds, Handbook of Physiology. Vol 4: Intrinsic regulatory system of the brain. Section 1: The nervous system. Bethesda, Maryland, USA: American Physiological Society; 647-676.
31. Fleckenstein AE, Hanson GR. 2003. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 479: 283-289.
32. Fuller RW, Hemrick-Luecke SK, Wong DT, Pearson D, Threlkeld PG, Hynes MD 3rd. 1983. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats. J Pharmacol Exp Ther 227:354-359.
33. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. 1998. Re-evaluation of the role of the dopamine transporter in dopamine homeostasis Brain Res Brain Rev 26: 148-153.
34. Gainetdinov RR, Caron MG. 2001. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J Am Acad Child Adolesc Psychiatry 40: 380-382.
35. Garris PA, Wightman RM. 1994. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 14: 442-450.
36. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YS. 1996. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58: 231-239.
37. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, Ding YS, et al. 1999. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 146: 93-100.
38. Giambalvo CT. 2003. Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes. Synapse 49: 125-133.
39. Gifford AN, Park MH, Kash TL, Herman LM, Park EH, Gatley SJ, et al. 2000. Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices. Naunyn Schmiedebergs Arch Pharmacol 362: 413-418.
40. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
41. Gnegy ME, Hong P, Ferrell ST. 1993. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 20: 289-298.
42. Gonzales-Lima F, Sadile A. 2000. Network operations revealed by brain metabolic mapping in a genetic model of hyperactivity and attention deficit: the naples high- and low-excitability rats. Neurosci Biobehav Rev 24: 157-160.
43. Grace AA. 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
44. Grace AA. 1995. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 37: 111-129.
45. Grace AA. 2001. Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: Solanto MV, Arnsten AFT, Xavier Castellanos F, eds, Stimulant Drugs and ADHD, Basic and Clinical Neuroscience. New York, NY, USA: Oxford University Press; 134-155.
46. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. 2000. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20: 1208-1215.
47. 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194: 47-56.
48. Hendley ED. 2000. WKHA rats with hyperactivity and hyperreactivity to stress: a review. Neurosci and Biobehav Rev 24: 41-44.
49. Hendley ED, Fan XM. 1992. Regional differences in brain norepinephrine and dopamine uptake kinetics in inbred rat strains with hypertension and/or hyperactivity. Brain Res 586: 44-52.
50. Huang YC, Wang SJ, Chiou LC, Gean PW. 2003. Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23: 10311-10320.
51. Inada T, Polk K, Jin C, Purser C, Hume A, Hoskins B, et al. 1992. Cocaine elevates striatal dopamine efflux in spontaneously hypertensive and Wistar-Kyoto rats. Brain Res Bull 28: 227-231.
52. Iwata S, Hewlett GH, Gnegy ME. 1997. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 26: 281-291.
53. Jones RS, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18: 1979-1986.
54. Justice JB Jr. 1993. Quantitative microdialysis of neurotransmitters. J Neurosci Meth 48: 263-276.
55. Khoshbouei H, Wang H, Lechleiter JD, Javitch A, Galli A. 2003. Amphetamine-induced dopamine efflux. J Biol Chem 278: 12070-12077.
56. Knardahl S, Sagvolden T. 1979. Open-field behavior of the spontaneously hypertensive rat. Behav Neural Biol 57: 187-200.
57. Kuczenski R, Segal DS, Cho AK, Melega W. 1995. Hippocampus norepinephrine, caudate dopamine, and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308-1317.
58. Kuczenski R, Segal DS. 2002. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22: 7264-7271.
59. Kujirai K, Przedborski S, Kostic V, Jackson-Lewis V, Fahn S, Cadet JL. 1990. Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat. Brain Res Bull 25: 703-709.
60. Kumai T, Tanaka M, Witanabe M, Nakura H, Tateishi T, Kobayashi S. 1996. Elevated tyrosine hydroxylase mRNA levels in medulla oblongata of spontaneously hypertensive rats. Brain Res Mol Brain Res 36: 197-199.
61. Leo D, Sorrentino E, Volpicelli F, Eyman M, Greco D, Viggiano et al. 2003. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 27:661-691.
62. Liang NY, Rutledge CO. 1982. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 31: 983-992.
63. Linthorst AC, De Lang H, De Jong W, Versteeg DH. 1991. Effect of the dopamine D2 receptor agonist quinpirole on the in vivo release of dopamine in the caudate nucleus of hypertensive rats. Eur J Pharm 201: 125-133.
64. Mack F, Bonisch H. 1979. Dissociation constants and lipophilicity of catecholamines and related compounds. Naunyn Schmiedebergs Arch Pharmacol 3: 1-9
65. Masuoka DT, Alcaraz AF, Schott HF. 1982. [3H]Dopamine release by d-amphetamine from striatal synaptosomes of reserpinized rats. Biochem Pharmacol 31: 1969-1974.
66. Middlemiss DN, Hutson PH. 1990. Measurement of the in vitro release of endogenous monoamine neurotransmitters as a means of identification of prejunctional receptors. J Neurosci Meth 34: 23-28.
67. Mook DM, Jeffry J. Neuringer A. 1993. Spontaneously hypertensive rats (SHR) readily learn to vary but not repeat instrumental responses. Behav Neural Biol 59: 126-135.
68. Mundorf ML, Hochstetler SE, Wightman RM. 1999. Amine weak bases disrupt vesicular storage and promote exocytosis in chromaffin cells. J Neurochem 73: 2397-2405.
69. Myers MM, Whittemore SR, Hendley ED. 1981. Changes in catecholamine neuronal uptake and receptor binding in the brains of spontaneously hypertensive rats (SHR). Brain Res 220: 325-338.
70. Nirenberg MJ, Chan J, Liu Y, Edwards RH, 1996. Pickel VM. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16: 4135-4145.
71. Oades RD. 1998. Frontal, temporal and lateralized brain function in children with attention-deficit hyperactivity disorder: a psychophysiological and neuropsychological viewpoint on development. Behav Brain Res 94: 83-95.
72. Papa M, Pellicano A, Cerbone C, Lamberti-DeMello, Menna T, Buono A, et al. 1995. Immediate early genes and brain DNA remodelling in the Naples high- and low-excitability rat lines following exposure to a spatial novelty. Brain Res Bull 37: 111-118.
73. Papa M, Sergeant JA, Sadile GA. 1998. Reduced transduction mechanism in the anterior accumbal interface of an animal model of Attention Deficit Hyperactivity Disorder. Behav Brain Res 94: 187-195.
74. Papa M, Diewald L, Carey MP, Esposito FJ, Gironi Carnevale UA, Sadile AG. 2002. A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and a posterior hyperfunctioning mesocorticolimbic system. Behav Brain Res. 130: 171-179.
75. Park MH, Park EH. 2000. Synaptic concentration of dopamine in rat striatal slices in relationship to [3H]raclopride binding to the dopamine D2 receptor. Arch Pharm Res 23: 360-366.
76. Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA. 2003. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem. 85: 898-910.
77. Patrick RL, Berkowitz AL, Regenstein AC. 1981. Effects of in vivo amphetamine administration on dopamine synthesis regulation in rat brain striatal synaptosomes. J Pharmacol Exp Ther 217: 686-691.
78. Pliszka SR. 2003. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 8: 253-258.
79. Reja V, Goodchild AK, Phillips JK, Pilowsky PM. 2002. Tyrosine hydroxylase gene expression in ventrolateral medulla oblongata of WKYY and SHR: a quantitative real-time polymerase chain reaction study. Auton Neurosci 98: 79-84.
80. Robbins TW. 2002. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163: 362-380.
81. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
82. Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. 1998. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of Attention-Deficit Hyperactivity Disorder. Behav Brain Res 94: 163-171.
83. Russell VA. 2000. The nucleus accumbens motorlimbic interface of the spontaneously hypertensive rat as studied in vitro by the superfusion slice technique. Neurosci Biobehav Rev 24: 133-136.
84. Russell VA. 2002. Hyperdopaminergic and hyponoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder- the spontaneously hypertensive rat. Behav Brain Res 130: 191-196.
85. Sadile AG, Lamberti C, Siegfried B, Welzl H. 1993. Circadian activity, nociceptive thresholds, nigrostriatal and mesolimbic dopaminergic activity in the Naples High- and Low-Excitability rat lines. Behav Brain Res 55: 17-27.
86. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. 2001. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21: 1413-1419.
87. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. 2002. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 22: 8705-87 10.
88. Sagvolden T, Hendley ED, Knardahl S. 1992a. Behavior of hypertensive and hyperactive rat strains: Hyperactivity is not unitarily determined. Physiol Behav 52: 49-57.
89. Sagvolden T, Metzger MA, Schiorbeck HK, Rugland AL, Spinnangr I, Sagvolden G. 1992b. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav Neural Biol 58: 103-112.
90. Sagvolden T, Metzger MA, Sagvolden G. 1993. Frequent reward eliminates differences in activity between hyperkinetic rats and controls. Behav Neural Biol 59: 225-229.
91. Sagvolden T, Sergeant JA. 1998. Attention deficit/hyperactivity disorder - from brain dysfunctions to behavior. Behav Brain Res 94: 1-10.
92. Sagvolden T. 2000. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit /hyperactivity disorder (ADHD). Neurosci Biobehav Rev 24: 31-39.
93. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. 2003. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87: 273-89.
94. Seeman P, Madras B. 2002. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav Brain Res 130: 79-83.
95. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. 1998. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. Neuroscience 18: 2697-2708.
96. Simpson D, Plosker GL. 2004. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64: 205-222.
97. Solanto MV. 1998. Neuropsychopharmacological mechanism of stimulant drug action in attention deficit/hyperactivity disorder: a review and integration. Behav Brain Res 94: 127-152.
98. Solanto MV. 2002. Dopamine dysfunction in ADHD: integrating clinical and basic neuroscience research. Behav Brain Res 130: 65-71.
99. Sonuga-Barke EJ, Taylor E, Sembi S, Smith J. 1992. Hyperactivity and delay aversion-I. The effect of delay on choice. J Child Psychol Psychiatry 33: 387-398.
100. Spencer TJ, Biederman J, Wilens TE, Faraone SV. 2002. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 Suppl 12: 3-9.
101. Stanley EF. 1993. Single calcium channels and acetylcholine release at a presynaptic nerve terminal. Neuron 11: 1007-1011.
102. Sulzer D, Rayport S. 1990. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5: 797-808.
103. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15: 4102-4108.
104. Swanson JM, Volkow ND. 2002. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 130: 73-78.
105. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic, et al. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94: 9938-9943.
106. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. 2003. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87: 1284-1295.
107. Viggiano D, Sadile AG. 2000. Hypertrophic A10 dopamine neurones in a rat model of attention-deficit hyperactivity disorder (ADHD). Neuroreport 11: 3677-3680.
108. Viggiano D, Grammatikopoulos G, Sadile AG. 2002. A morphometric evidence for a hyperfunctioning mesolimbic system in an animal model of ADHD. Behav Brain Res 130: 181-189.
109. Viggiano D, Ruocco LA, Pignatelli M, Grammatikopoulos G, Sadile AG. 2003. Prenatal elevation of endocannabinoids corrects the unbalance between dopamine systems and reduces activity in the Naples High Excitability rats. Neurosci Biobehav Rev 27: 129-139.
110. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, et al. 1999. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65: PL7-PL12.
111. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, et al. 2002. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43: 181-187.
112. Watanabe Y, Fujita M, Ito Y, Okada T, Kusuoka H, Nishimura T. 1997. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38: 470-474.
113. Westerink BH. 2000. Analysis of biogenic amines in microdialysates of the brain. J Chromatogr B Biomed Sci Appl 747: 21-32.
114. Whalen CK, Henker B, Buhrmester D, Hinshaw SP, Huber A, Laski K. 1989. Does stimulant medication improve the peer status of hyperactive children? J Consult Clin Psychol 57: 545-549.
115. Whittaker VP, Michaelson IA, Kirkland RJ. 1964. The separation of synaptic vesicles from nerve-ending particles ('synaptosomes'). Biochem J 90: 293-303.
116. Wieczorek WJ, Kruk ZL. 1994. Differential action of (+)-amphetamine on electrically evoked dopamine overflow in rat brain slices containing corpus striatum and nucleus accumbens. Br J Pharmacol 111: 829-836.
117. Wilens TE, Biederman J, Spencer TJ, Prince J. 1995. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 15: 270-279.
118. Woodward DJ, Chang JY, Janak P, Azarov A, Anstrom K. 1999. Mesolimbic neuronal activity across behavioral states. Ann NY Acad Sci 877: 91-112.
119. Wyss JM, Fisk G, van Groen T. 1992. Impaired learning and memory in mature spontaneously hypertensive rats. Brain Res 592: 135-140.
120. Yamamoto BK, Novotney S. 1998. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71: 274-280.
121. Yamory Y. 1984. Development of the spontaneously hypertensive rat (SHR) and of various spontaneous rat models and implications. In: De Jong W, ed, Handbook of Hypertension. New York, NY, USA: Elsevier; 224-239.
122. +-evoked [3H]dopamine release in striatal and frontal cortical synaptosomes of normotensive and spontaneous-hypertensive rats. Neurochem Res 26: 1271-1275.
123. Yu ZJ, Lim DK, Hoskins B, Rockhold RW, Ho IK. 1990. Effects of acute and subacute cocaine administration on the CNS dopaminergic system in Wistar-Kyoto and spontaneously hypertensive rats: I. Levels of dopamine and metabolites. Neurochem Res 15: 613-619.
124. Zaczek R, Culp S, De Souza EB. 1991. Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257: 830-835.
125. Zham DS, Heimer L. 1993. Specificity in the efferent projection of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J Comp Neurol 327: 220-232.
126. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, et al. 2001. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98: 1982-1987.